Brilinta Clinical Experience Investigation - BRLCEIACS/OMI

To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as “BRILINTA”) in clinical practice in the post-marketing phase. (1) Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on bleeding, dyspnoea and bradyarrhythmia so as to investigate onset, outcome, treatment for the event, and risk factors for these events, etc. (2) Profile and incidence of ADRs not expected from “Precautions for Use” of the ticagrelor JPI (3) Efficacy: Profile and incidence of cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke) (4) Factors which may affect safety or efficacy of ticagrelor